Please use this identifier to cite or link to this item:
Title: Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal
Authors: Zhao, X.
Chen, A.
Yan, X.
Zhang, Y.
He, F.
Hayashi, Y.
Dong, Y.
Rao, Y.
Li, B.
Conway, R.M.
Maiques-Diaz, A.
Elf, S.E.
Huang, N.
Zuber, J.
Xiao, Z.
Tse, W.
Tenen, D.G. 
Wang, Q.
Chen, W.
Mulloy, J.C.
Nimer, S.D.
Huang, G.
Issue Date: 13-Mar-2014
Citation: Zhao, X., Chen, A., Yan, X., Zhang, Y., He, F., Hayashi, Y., Dong, Y., Rao, Y., Li, B., Conway, R.M., Maiques-Diaz, A., Elf, S.E., Huang, N., Zuber, J., Xiao, Z., Tse, W., Tenen, D.G., Wang, Q., Chen, W., Mulloy, J.C., Nimer, S.D., Huang, G. (2014-03-13). Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal. Blood 123 (11) : 1729-1738. ScholarBank@NUS Repository.
Abstract: RUNX1/CBFβ (core binding factor [CBF]) is a heterodimeric transcription factor complex that is frequently involved in chromosomal translocations, point mutations, or deletions in acute leukemia. The mixed lineage leukemia (MLL) gene is also frequently involved in chromosomal translocations or partial tandem duplication in acute leukemia. The MLL protein interacts with RUNX1 and prevents RUNX1 from ubiquitin-mediated degradation. RUNX1/CBFβ recruits MLL to regulate downstream target genes. However, the functional consequence of MLL fusionson RUNX1/CBFβ activity has not been fully understood. In this report, we show that MLL fusion proteins and the N-terminal MLL portion of MLL fusions downregulate RUNX1 and CBFβ protein expression via the MLL CXXC domain and flanking regions. We confirmed this finding in Mll-Af9 knock-in mice and human M4/M5 acutemyeloid leukemia (AML) cell lines, with or without MLL translocations, showing that MLL translocations cause a hypomorph phenotype of RUNX1/CBFβ. Overexpression of RUNX1 inhibits the development of AML in Mll-Af9 knock-in mice; conversely, further reducing Runx1/Cbfβ levels accelerates MLL-AF9-mediated AML in bone marrow transplantation assays. These data reveal a newly defined negative regulation of RUNX1/CBFβ by MLL fusion proteins and suggest that targeting RUNX1/CBFβ levels may be a potential therapy for MLLs. © 2014 by The American Society of Hematology.
Source Title: Blood
ISSN: 15280020
DOI: 10.1182/blood-2013-03-489575
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Jun 17, 2021


checked on Jun 8, 2021

Page view(s)

checked on Jun 6, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.